Hjem › T-celle-lymfom
T-celle-lymfom kliniske forsøg rekrutterer i USA
35 studier for T-celle-lymfom rekrutterer deltagere på steder over hele USA.
Byer med flest studier
- New York City, NY13 studier
- Philadelphia, PA10 studier
- Baldwin Park, CA9 studier
- Boston, MA9 studier
- Houston, TX8 studier
- Atlanta, GA8 studier
- Chicago, IL6 studier
- Columbus, OH6 studier
- Seattle, WA6 studier
- Rochester, MN6 studier
- New Haven, CT5 studier
- Miami, FL5 studier
- Ann Arbor, MI4 studier
- Scottsdale, AZ4 studier
- Baltimore, MD4 studier
- Portland, OR4 studier
- Durham, NC4 studier
- Cedar Rapids, IA4 studier
- St. Louis, MO4 studier
- Charlottesville, VA4 studier
- Los Angeles, CA3 studier
- Aurora, CO3 studier
- San Diego, CA3 studier
- Charlotte, NC3 studier
- Madison, WI3 studier
- San Francisco, CA3 studier
- Edison, NJ3 studier
- Omaha, NE3 studier
- Rochester, NY3 studier
- Salt Lake City, UT3 studier
- Cincinnati, OH3 studier
- Staten Island, NY3 studier
- Queens, NY3 studier
- East Norwalk, CT3 studier
- New Rochelle, NY3 studier
- Milwaukee, WI3 studier
- Tampa, FL3 studier
- Indianapolis, IN3 studier
- Minneapolis, MN3 studier
- Denver, CO3 studier
Efter delstat
- Arizona5 studier
- Californien13 studier
- Colorado6 studier
- Connecticut5 studier
- Florida8 studier
- Georgia8 studier
- Illinois7 studier
- Indiana3 studier
- Iowa4 studier
- Maryland4 studier
- Massachusetts9 studier
- Michigan5 studier
- Minnesota9 studier
- Missouri4 studier
- Nebraska3 studier
- New Jersey4 studier
- New York15 studier
- North Carolina6 studier
- Ohio8 studier
- Oklahoma3 studier
- Oregon4 studier
- Pennsylvania12 studier
- Texas9 studier
- Utah3 studier
- Virginia5 studier
- Washington6 studier
- Wisconsin5 studier
Nyligt opdaterede studier
Officiel studietekst (engelsk)
Testing the Addition of Duvelisib or CC-486 to the Usual Treatment for Peripheral T-Cell Lymphoma
RekruttererFase 2
Alder 18 og opefter · Alle køn · Opdateret 2. okt. 2026 · NCT04803201Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution
RekruttererObservationsstudie
Alder 0 til 38 · Alle køn · Opdateret 1. okt. 2026 · NCT06131801Soquelitinib vs Standard of Care in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma Not Otherwise Specified, Follicular Helper T-cell Lymphomas, or Systemic Anaplastic Large-cell Lymphoma
RekruttererFase 3
Alder 18 og opefter · Alle køn · Opdateret 25. sep. 2026 · NCT06561048BI-1808 as a Single Agent and With Pembrolizumab (KEYTRUDA® ) in Treatment of Advanced Malignancies(Keynote-D20)
RekruttererFase 1/2
Alder 18 og opefter · Alle køn · Opdateret 18. sep. 2026 · NCT04752826Testing Whether High Dose Chemotherapy and Infusion of the Patients' Own Stem Cells Improves Survival in Patients With Peripheral T-cell Lymphoma Who Achieved a Complete Response at the End of the Initial Chemotherapy
RekruttererFase 3
Alder 18 til 75 · Alle køn · Opdateret 14. sep. 2026 · NCT06724237A Study of Ruxolitinib and Duvelisib in People With Lymphoma
RekruttererFase 1
Alder 18 og opefter · Alle køn · Opdateret 9. sep. 2026 · NCT05010005A Phase 2 Study of PTX 100 in Patients With Relapsed/Refractory CTCL
RekruttererFase 2
Alder 18 og opefter · Alle køn · Opdateret 9. sep. 2026 · NCT06854653A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas
RekruttererFase 1/2
Alder 18 og opefter · Alle køn · Opdateret 19. aug. 2026 · NCT04104776Phase 1 Study of JV-394 Autologous Anti-CD94 CAR T for r/r CD94+ T/NK Cell Neoplasms
RekruttererFase 1
Alder 18 og opefter · Alle køn · Opdateret 12. aug. 2026 · NCT07382817Adding Dasatinib Or Venetoclax To Improve Responses In Children With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia (ALL) Or Lymphoma (T-LLY) Or Mixed Phenotype Acute Leukemia (MPAL)
RekruttererFase 2
Alder 1 til 18 · Alle køn · Opdateret 10. aug. 2026 · NCT06390319CD45BE-HSPC + CART-45 Cells
RekruttererFase 1
Alder 18 og opefter · Alle køn · Opdateret 10. aug. 2026 · NCT07451054Sample Collection for Ongoing Research and Product Evaluation Study - Non-Hodgkin Lymphoma (SCORE-NHL)
RekruttererObservationsstudie
Alder 18 og opefter · Alle køn · Opdateret 6. aug. 2026 · NCT07750886Duvelisib Maintenance for the Treatment of Peripheral T-Cell Lymphomas
RekruttererFase 2
Alder 18 og opefter · Alle køn · Opdateret 5. aug. 2026 · NCT07293403Durvalumab With or Without Lenalidomide in Treating Patients With Relapsed or Refractory Cutaneous or Peripheral T Cell Lymphoma
RekruttererFase 1/2
Alder 18 og opefter · Alle køn · Opdateret 31. jul. 2026 · NCT03011814Anti-CD7 CAR-T Cells in Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia or Lymphoma
RekruttererFase 1
Alder 0 til 29 · Alle køn · Opdateret 7. jul. 2026 · NCT06934382Evaluation of Human Immune Responses Vaccination in Patients With Lymphoma
RekruttererObservationsstudie
Alder 18 og opefter · Alle køn · Opdateret 6. jul. 2026 · NCT03501576Allo HSCT Using RIC and PTCy for Hematological Diseases
RekruttererFase 2
Op til 75 år · Alle køn · Opdateret 6. jul. 2026 · NCT05805605Intravenous Vesicular Stomatitis Virus in Patients With Peripheral T-cell Lymphoma
RekruttererFase 1
Alder 18 og opefter · Alle køn · Opdateret 1. jul. 2026 · NCT06508463CD4CAR for CD4+ Leukemia and Lymphoma
RekruttererFase 1
Alder 12 og opefter · Alle køn · Opdateret 24. jun. 2026 · NCT03829540A Phase 1/2 Study of STP938 (Dencatistat) for Adult Subjects With Relapsed/Refractory B-Cell and T-Cell Lymphomas
RekruttererFase 1/2
Alder 18 og opefter · Alle køn · Opdateret 16. jun. 2026 · NCT05463263Pembrolizumab and Brentuximab Vedotin in Subjects With Relapsed/Refractory T-cell Lymphoma
RekruttererFase 2
Alder 18 og opefter · Alle køn · Opdateret 11. jun. 2026 · NCT05313243A Vaccine (VSV-hIFNβ-NIS) With or Without Cyclophosphamide and Combinations of Ipilimumab, Nivolumab, and Cemiplimab in Treating Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia or Lymphoma
RekruttererFase 1
Alder 18 og opefter · Alle køn · Opdateret 10. jun. 2026 · NCT03017820Ruxolitinib in Combination With CHOP Chemotherapy for the Treatment of Untreated Nodal T-Follicular Helper Cell Lymphomas
RekruttererFase 1
Alder 18 og opefter · Alle køn · Opdateret 5. jun. 2026 · NCT07278856A Registry for People With T-cell Lymphoma
RekruttererObservationsstudie
Alle aldre · Alle køn · Opdateret 20. maj 2026 · NCT05978141Pralatrexate With Bendamustine and Total-Body Irradiation Followed by Donor Stem Cell Transplant for the Treatment of Relapsed or Refractory T-Cell Non-Hodgkin Lymphoma
RekruttererFase 1/2
Alder 18 og opefter · Alle køn · Opdateret 11. maj 2026 · NCT07225985Fra ClinicalTrials.gov, data hentet 3. okt. 2026. Hver studie har sine egne kvalifikationskrav; studieteamet afgør, hvem der kan deltage.